Intellia Therapeutics Total Assets Growth & History (NTLA)
Intellia Therapeutics's total assets was $842.1M for fiscal 2025.
View full Intellia Therapeutics company overviewIntellia Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $842.1M | −$348.9M | −29.29% |
| 2024 | 2024-12-31 | $1.19B | −$110.0M | −8.45% |
| 2023 | 2023-12-31 | $1.30B | −$219.1M | −14.42% |
| 2022 | 2022-12-31 | $1.52B | $225.7M | +17.43% |
| 2021 | 2021-12-31 | $1.29B | $618.1M | +91.40% |
| 2020 | 2020-12-31 | $676.3M | $342.0M | +102.32% |
| 2019 | 2019-12-31 | $334.3M | −$13.0M | −3.75% |
| 2018 | 2018-12-31 | $347.3M | −$28.9M | −7.69% |
| 2017 | 2017-12-31 | $376.2M | $77.3M | +25.84% |
| 2016 | 2016-12-31 | $299.0M | $216.8M | +263.98% |
| 2015 | 2015-12-31 | $82.1M | — | — |
Intellia Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $857.2M | −$41.7M | −4.64% |
| Q1 2026 | 2026-03-31 | $758.8M | −$227.4M | −23.06% |
| Q4 2025 | 2025-12-31 | $842.1M | −$348.9M | −29.29% |
| Q3 2025 | 2025-09-30 | $925.3M | −$248.1M | −21.14% |
| Q2 2025 | 2025-06-30 | $898.9M | −$292.6M | −24.56% |
| Q1 2025 | 2025-03-31 | $986.2M | −$273.4M | −21.71% |
| Q4 2024 | 2024-12-31 | $1.19B | −$110.0M | −8.45% |
| Q3 2024 | 2024-09-30 | $1.17B | −$70.0M | −5.63% |
| Q2 2024 | 2024-06-30 | $1.19B | −$131.7M | −9.95% |
| Q1 2024 | 2024-03-31 | $1.26B | −$158.3M | −11.16% |
| Q4 2023 | 2023-12-31 | $1.30B | −$219.1M | −14.42% |
| Q3 2023 | 2023-09-30 | $1.24B | $158.9M | +14.65% |
| Q2 2023 | 2023-06-30 | $1.32B | $212.8M | +19.17% |
| Q1 2023 | 2023-03-31 | $1.42B | $215.1M | +17.88% |
| Q4 2022 | 2022-12-31 | $1.52B | $225.7M | +17.43% |
| Q3 2022 | 2022-09-30 | $1.08B | −$250.5M | −18.76% |
| Q2 2022 | 2022-06-30 | $1.11B | $438.2M | +65.18% |
| Q1 2022 | 2022-03-31 | $1.20B | $485.9M | +67.78% |
| Q4 2021 | 2021-12-31 | $1.29B | $618.1M | +91.40% |
| Q3 2021 | 2021-09-30 | $1.33B | $876.4M | +191.12% |
| Q2 2021 | 2021-06-30 | $672.2M | $181.4M | +36.96% |
| Q1 2021 | 2021-03-31 | $716.9M | $402.1M | +127.76% |
| Q4 2020 | 2020-12-31 | $676.3M | $342.0M | +102.32% |
| Q3 2020 | 2020-09-30 | $458.6M | $111.9M | +32.29% |
| Q2 2020 | 2020-06-30 | $490.8M | $138.4M | +39.27% |
| Q1 2020 | 2020-03-31 | $314.8M | −$29.6M | −8.60% |
| Q4 2019 | 2019-12-31 | $334.3M | −$13.0M | −3.75% |
| Q3 2019 | 2019-09-30 | $346.6M | $25.4M | +7.91% |
| Q2 2019 | 2019-06-30 | $352.4M | $12.7M | +3.73% |
| Q1 2019 | 2019-03-31 | $344.4M | −$15.2M | −4.22% |
| Q4 2018 | 2018-12-31 | $347.3M | −$28.9M | −7.69% |
| Q3 2018 | 2018-09-30 | $321.2M | $72.1M | +28.92% |
| Q2 2018 | 2018-06-30 | $339.8M | $74.8M | +28.23% |
| Q1 2018 | 2018-03-31 | $359.5M | $80.3M | +28.75% |
| Q4 2017 | 2017-12-31 | $376.2M | $77.3M | +25.84% |
| Q3 2017 | 2017-09-30 | $249.2M | −$52.3M | −17.35% |
| Q2 2017 | 2017-06-30 | $265.0M | −$45.6M | −14.70% |
| Q1 2017 | 2017-03-31 | $279.3M | $203.7M | +269.69% |
| Q4 2016 | 2016-12-31 | $299.0M | $216.8M | +263.98% |
| Q3 2016 | 2016-09-30 | $301.5M | — | — |
| Q2 2016 | 2016-06-30 | $310.6M | — | — |
| Q1 2016 | 2016-03-31 | $75.5M | — | — |
| Q4 2015 | 2015-12-31 | $82.1M | — | — |
Intellia Therapeutics total assets trends
Over the last five fiscal years, Intellia Therapeutics's total assets increased from $676.3M to $842.1M, a change of $165.8M. The latest reported quarter, Q2 2026, shows $857.2M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Intellia Therapeutics source filings ↗